Extended half-life coagulation factors: A new era in the management of hemophilia patients [Uzatılmış yarı ömürlü koagülasyon faktörleri: Hemofili tedavisinde yeni bir dönem]

Basit Öğe Kaydı
dc.contributor.authorAr M.C.
dc.contributor.authorBalkan C.
dc.contributor.authorKavaklı K.
dc.date.accessioned2019-10-27T08:01:22Z
dc.date.available2019-10-27T08:01:22Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractDespite effective factor replacement and various treatment schedules, there remain several challenges and unmet needs in the prophylactic treatment of hemophilia limiting its adoption and thereby posing an increased risk of spontaneous bleeding. In this regard, extended half-life (EHL) recombinant factor VIII (rFVIII) and factor IX (rFIX) products promise optimal prophylaxis by decreasing the dose frequency, increasing the compliance, and improving the quality of life without compromising safety and efficacy. EHL products might lead to higher trough levels without increasing infusion frequency, or could facilitate the ability to maintain trough levels while reducing infusion frequency. This paper aims to provide a comprehensive review of the rationale for developing EHL coagulation factors and their utility in the management of hemophilia, with special emphasis on optimal techniques for half-life extension and criteria for defining EHL coagulation factors, as well as indications, efficacy, and safety issues of the currently available EHL-rFVIII and EHL-rFIX products. Potential impacts of these factors on quality of life, health economics, and immune tolerance treatment will also be discussed alongside the challenges in pharmacokinetic-driven prophylaxis and difficulties in monitoring the EHL products with laboratory assays. © 2019 by Turkish Society of Hematology.en_US
dc.description.sponsorshipTürk Hematoloji Derneği Türk Hematoloji Derneğien_US
dc.description.sponsorshipThe manuscript was prepared by the Hemophilia Scientific Subcommittee of the Turkish Society of Hematology. Sobi has provided financial support to the Turkish Society of Hematology to cover costs for editorial assistance, but has not influenced the content. -- Financial Disclosure: There are no financial conflicts of interest to disclose except that Sobi has provided a non-restricted medical grant to the Turkish Society of Hematology to cover the expenses of editorial assistance. --en_US
dc.identifier.doi10.4274/tjh.galenos.2019.2018.0393en_US
dc.identifier.endpage154en_US
dc.identifier.issn1300-7777
dc.identifier.issue3en_US
dc.identifier.pmid31088040en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage141en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2019.2018.0393
dc.identifier.urihttps://hdl.handle.net/11454/24975
dc.identifier.volume36en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Society of Hematologyen_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectExtended half-life productsen_US
dc.subjectFactor replacement therapyen_US
dc.subjectHemophiliaen_US
dc.subjectLaboratory assaysen_US
dc.subjectPharmacokineticsen_US
dc.subjectQuality of lifeen_US
dc.titleExtended half-life coagulation factors: A new era in the management of hemophilia patients [Uzatılmış yarı ömürlü koagülasyon faktörleri: Hemofili tedavisinde yeni bir dönem]en_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu